Institution
West Los Angeles College
Education•Culver City, California, United States•
About: West Los Angeles College is a education organization based out in Culver City, California, United States. It is known for research contribution in the topics: Population & Health care. The organization has 2128 authors who have published 2110 publications receiving 102110 citations. The organization is also known as: West LA College & West L.A. College.
Topics: Population, Health care, Bipolar disorder, Poison control, Dementia
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities.
Abstract: Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab. Patients and Methods Patients were randomly assigned to receive aflibercept (4 mg/kg intravenously; 612 patients) or placebo (614 patients) every 2 weeks in combination with FOLFIRI. Treatment was administered until disease progression or unacceptable toxicity. The primary end point was overall survival. Results Adding aflibercept to FOLFIRI significantly improved overall survival relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; P .0032) with median survival times of 13.50 versus 12.06 months, respectively. Aflibercept also significantly improved progression-free survival (PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P .0001), with median PFS times of 6.90 versus 4.67 months, respectively. The effects on overall survival and PFS exhibited a consistent trend across prespecified subgroup analyses, including bevacizumab pretreated patients. Response rate was 19.8% (95% CI, 16.4% to 23.2%) with aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo plus FOLFIRI (P .0001). Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti–vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities.
1,185 citations
••
TL;DR: The five steps in the initial development of an evidence based guideline are considered and the results of their combined experience in guideline development in North America and Britain are presented.
Abstract: This is the second in a series of four articles on issues in the development and use of clinical guidelines.
1,135 citations
••
West Los Angeles College1, Veterans Health Administration2, University of California, Los Angeles3, Icahn School of Medicine at Mount Sinai4, United States Department of Veterans Affairs5, University of Alabama at Birmingham6, Virginia Commonwealth University7, University of Florida8, University of Miami9, Loyola University Chicago10
TL;DR: As initial intravenous treatment for overt generalized convulsive status epilepticus, lorazepam is more effective than phenytoin and it is easier to use.
Abstract: Background and Methods Although generalized convulsive status epilepticus is a life-threatening emergency, the best initial drug treatment is uncertain. We conducted a five-year randomized, double-blind, multicenter trial of four intravenous regimens: diazepam (0.15 mg per kilogram of body weight) followed by phenytoin (18 mg per kilogram), lorazepam (0.1 mg per kilogram), phenobarbital (15 mg per kilogram), and phenytoin (18 mg per kilogram). Patients were classified as having either overt generalized status epilepticus (defined as easily visible generalized convulsions) or subtle status epilepticus (indicated by coma and ictal discharges on the electroencephalogram, with or without subtle convulsive movements such as rhythmic muscle twitches or tonic eye deviation). Treatment was considered successful when all motor and electroencephalographic seizure activity ceased within 20 minutes after the beginning of the drug infusion and there was no return of seizure activity during the next 40 minutes. Analyse...
1,130 citations
••
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Abstract: Background Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption. Methods Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy. The patients were stratified according to whether they were receiving first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy at entry into the study. Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration >12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and quality of life were assessed monthly. Results Among 392 treated patients, th...
1,024 citations
••
TL;DR: A hypothetical model of Alzheimer's disease as a uniquely human brain disorder rooted in its exceptional process of myelination is presented, offering a framework that explains the anatomical distribution and progressive course of AD pathology, some of the failures of promising therapeutic interventions, and suggests further testable hypotheses as well as novel approaches for intervention efforts.
879 citations
Authors
Showing all 2134 results
Name | H-index | Papers | Citations |
---|---|---|---|
John E. Morley | 154 | 1377 | 97021 |
Jeffrey L. Cummings | 148 | 833 | 116067 |
John P. Moore | 136 | 522 | 60331 |
Paul G. Shekelle | 132 | 601 | 101639 |
Steven J. Jacobsen | 123 | 662 | 62716 |
Robert L. Modlin | 112 | 329 | 42972 |
Ronald W. Busuttil | 109 | 819 | 46281 |
Susan Bonner-Weir | 106 | 313 | 40827 |
Michael F. Green | 106 | 485 | 45707 |
Clifford Y. Ko | 104 | 514 | 37029 |
Jim Mintz | 103 | 473 | 36469 |
Enrique Rozengurt | 99 | 467 | 31267 |
Charles L. Bennett | 99 | 491 | 106010 |
Shalender Bhasin | 99 | 453 | 38734 |
Lori L. Altshuler | 99 | 355 | 30472 |